BHRT and Pellet Therapy for Hormonal Balance

Discover how BHRT combined with pellet therapy can help balance your hormones and improve your overall well-being.

Abstract

In this educational post, I guide you through a practical, evidence-informed journey to evaluate and manage menopausal and andropausal symptoms using integrative, chiropractic-informed, and functional strategies. I explain how I risk-stratify candidates for hormone pellet therapy, optimize thyroid physiology and micronutrient levels (such as vitamin D and ferritin), and tailor testosterone and estradiol/progesterone regimens. You will see how standardized symptom checklists, comprehensive labs, QR-coded education, and structured follow-up cadence reduce complications and improve outcomes. I also detail my low-trauma micro-tunneling pellet technique and show where integrative chiropractic care supports autonomic regulation, sleep quality, pelvic mechanics, and pain reduction, amplifying endocrine benefits. Throughout, I incorporate the latest research from leading investigators and link directly to peer-reviewed sources to support each clinical step. My clinical observations, documented at PushAsRx and on my professional profile, add real-world nuance to this whole-person approach.

The Patient Journey: Why Workflow Matters for Hormone Optimization

I learned early that a clear care pathway transforms outcomes. When we delayed scheduling and relied on patients to “call when ready,” adherence and results suffered. Standardizing the journey reduced friction and built trust.

• Reduces cognitive load: Menopause and andropause are overwhelming. A predictable pathway lowers decision fatigue and keeps patients engaged (Koonce et al., 2015).
• Improves data quality: Timely labs aligned with symptom timing provide clean comparisons and actionable physiology.
• Enhances safety: Checklists, lab gates, and standardized side-effect briefings reduce preventable complications.
• Builds trust: Short, QR-linked videos pre-answer common questions about costs, timelines, side effects, and follow-up cadence.

I deploy concise, two-minute videos via QR codes so patients arrive informed. Evidence suggests pre-visit education improves comprehension and adherence for chronic-care interventions (Koonce et al., 2015).

Streamlined Onboarding: Symptom Scales and QR-Coded Education

I begin with validated symptom scales to anchor subjective experience to reproducible metrics:

• Women: Menopause Rating Scale (MRS) and a BHRT symptom checklist (Heinemann et al., 2004).
• Men: Aging Male Symptoms (AMS) scale, which focuses on sexual function, vitality, mood, sleep, and strength (Daig et al., 2003).

Why scores matter:

• Correlate with hormone status and autonomic dysregulation, guiding dose calibration and tracking benefit over time (Greendale et al., 2019).
• Create a shared language for progress and side effects to elevate patient engagement.

I pair onboarding with a QR “playlist”:

• Fundamentals: What hormones do; what to expect from therapy; how lifestyle affects outcomes.
• Practicalities: Costs, timelines, side effects, and follow-up.
• Lab literacy: What each test measures and why target ranges matter.

Comprehensive Lab Strategy: Foundations Before Therapy

Starting therapy without foundations is like building on sand. I order baseline labs before initiating treatment:

• CBC, CMP: Screen for anemia, hepatic, and renal issues.
• Ferritin: Low ferritin levels worsen fatigue and confound thyroid interpretation; optimizing iron status supports mitochondrial enzymes and builds tolerance (Camaschella, 2015).
• 25-hydroxyvitamin D: Influences muscle function, immunity, and steroidogenesis (Carlberg & Haq, 2020).
• Thyroid panel (TSH, free T4, free T3): Attention to free hormones is important in symptomatic patients, particularly in peri- and postmenopause (Taylor et al., 2018).
• Fasting lipids, HbA1c: Identify insulin resistance and cardiometabolic risk (Stuenkel et al., 2015; Bhasin et al., 2018).
• Sex hormones:

• Women: Estradiol, progesterone (if cycling), DHEA-S, total and free testosterone, SHBG.
• Men: Total and free testosterone, SHBG, estradiol, plus LH/FSH when indicated. Free fractions often tell the story better due to SHBG variability (Rastrelli et al., 2018).

• Inflammation markers: hs-CRP, ferritin trend; homocysteine or cytokine surrogates as indicated.

I translate lab results into clear narratives: for example, a free testosterone that is “essentially zero” in the setting of high SHBG and low libido or loss of lean mass is clinically actionable.

The Consultation: Co-Creating a Plan With Options and Safety

During consultation, I align symptoms and lab data and co-create a plan:

• Options menu: Pellets, injectables, transdermals, oral micronized progesterone, and non-hormonal supports.
• Side-effect briefing: A succinct counseling session plus a two-minute QR video on risks, red flags, and next steps.
• Next steps scheduled: We schedule follow-up labs and visits before the patient leaves. For pellets, I reassess women around 14 weeks and tailor men’s intervals to kinetics and symptoms. This single step dramatically improved retention and outcomes.

Assessing Hormone Therapy- Video

Physiology First: The Neuroendocrine-Metabolic Network

Hormones are signals embedded in a complex network. The following principles shape my protocols:

• Thyroid-tissue signaling: TSH is upstream. Patients may have TSH levels of 3.5–4.0 mIU/L, with low-normal free T3, and persistent symptoms. Narrower optimal ranges and attention to free hormones can help symptomatic peri/postmenopausal patients, especially when estrogen shifts alter binding and tissue responsiveness (Taylor et al., 2018).
• SHBG and bioavailability: Elevated SHBG can “starve” tissues. Restoring physiologic free fractions improves neuromuscular function, mood, and metabolic flexibility (Davis & Wahlin-Jacobsen, 2015).
• Ferritin and thyroid/androgen interplay: Ferritin supports thyroid peroxidase and mitochondrial enzymes. Levels below ~50–70 ng/mL are often associated with hair loss, fatigue, and poor response to thyroid optimization (Camaschella, 2015).
• Vitamin D and steroidogenesis: Vitamin D receptor signaling influences muscle, immune tone, and gonadal sensitivity. I generally aim for steady daily dosing to reach mid-normal 25(OH)D (Carlberg & Haq, 2020).
• Adiposity shift in menopause: Declining estradiol and androgens alter adipocyte biology, insulin signaling, and sympathetic tone, promoting visceral fat and sarcopenia. Balanced estradiol, physiologic androgens, protein-forward nutrition, and progressive resistance training counter this trajectory (Lovejoy et al., 2008; Dieli-Conwright et al., 2018).

Integrative Chiropractic Care: Where Structure Meets Endocrine Function

Integrative chiropractic is not an add-on—it is a force multiplier:

• Autonomic regulation: Cervical and thoracic dysfunction can drive sympathetic dominance, manifesting as sleep fragmentation, palpitations, and anxiety. Gentle, targeted spinal manipulation and soft-tissue work can improve heart rate variability and parasympathetic tone, thereby stabilizing HPA-axis signaling (Martins et al., 2018; Haavik & Murphy, 2018).
• Pain and endocrine balance: Chronic pain elevates cortisol and catecholamines, impairing sex hormone signaling and thyroid conversion. Restoring joint mechanics and reducing nociceptive load lowers inflammatory cytokine levels, enabling better training adherence and amplifying anabolic signals.
• Functional movement:

• Early: Motor control, breathing mechanics, and joint centration.
• Strength: Progressive overload for muscle protein synthesis and insulin sensitivity.
• Recovery: Sleep hygiene and breath work.

From my clinic observations at PushAsRx and my LinkedIn cases, I’ve found that blending hormone optimization with corrective exercise and manual care yields sharper improvements in body composition, energy, and mood.

• PushAsRx: https://pushasrx.com/
• Professional profile: https://www.linkedin.com/in/dralexjimenez/

Hormone Pellet Therapy: Why and How I Use It

Pellets provide steady pharmacokinetics, which many patients prefer for symptom control and adherence (Davis & Wahlin, 2023). I integrate pellets within a wider framework of consent, monitoring, and biomechanical support.

• Shared decision-making: We review alternatives (transdermal, oral, injectable) and document risks, benefits, and procedural specifics.
• Breast health and imaging: For estrogen-containing regimens, I discuss age- and risk-appropriate mammography and adjuncts for dense breasts. A mammogram is a screening tool, not a diagnosis; abnormal findings direct further evaluation (Nelson et al., 2016). Route, dose, and metabolic context matter for risk-benefit calculus (Manson et al., 2023).
• Consent as pedagogy: Explicit education minimizes “no one told me” issues and reinforces nightly micronized progesterone for endometrial safety when using estrogen (Stuenkel et al., 2022).

Procedural Technique: Low-Trauma Micro-Tunneling for Fewer Complications

Technique matters. Many patients abandon pellets due to traumatic insertion experiences. I use micro-tunneling to reduce hematoma, extrusion, and scarring.

• Preparation:

• Positioning, sterile field, and instrument layout.
• Two-step local anesthesia: proximal wheal at incision, then distal infiltration, matching trocar length to anesthetize the tract.

• Incision orientation: I align with skin tension lines (often the belt line near the lateral hip) to minimize wound gaping and improve cosmetic outcomes. Aligning with Langer’s lines reduces mechanotransduction stress and supports organized collagen deposition (Garg et al., 2020; Payne et al., 2014).
• Trocar advancement: I use a blunt, conical tip to separate tissue planes rather than cut them, reducing capillary injury and hematoma risk (Nyman et al., 2017; Patel et al., 2021). My hand is anchored on the patient for fine motor control; resistance means reassess angle—never force.
• Pocket creation and pellet placement: Short, smooth, linear tracts prevent stacking and incision-line contact. No gaping pocket; gentle compression; closure with steri-strips and a T-shaped outer tape to protect tension-sharing and prevent accidental strip removal.
• Post-procedure instructions: Keep steri-strips dry; avoid soaking, swimming, and sweaty workouts for approximately five days; minimize strain and lateral bending to reduce shear across the closure. Early wound management supports the hemostasis, inflammation, proliferation, and remodeling phases, reducing infection rates and improving scar quality (WHO, 2016; Edmiston et al., 2013).

Patients often fear deep visceral injury; I explain why a blunt trocar advancing within the subcutaneous plane cannot penetrate resistant deep tissues when used correctly. Ultrasound guidance is available for anatomically complex or high-BMI cases.

Dosing Strategy: Start Low, Adjust With Data, Avoid Overshoot

Initial rounds must acknowledge “empty tanks.” The first pellet cycle may require higher dosing than long-term maintenance; once tissues reach steady state, less hormone is needed to maintain benefits.

• Round 1: Weight-, SHBG-, and symptom-guided dosing.
• Round 2+: Reassess symptoms and labs. A “full tank” physiology takes less to maintain effects.
• Nuance:

• Women with high SHBG and very low free T often need cautious titration; if sleep is the limiter, I optimize progesterone timing, sleep architecture, and stress physiology rather than reflexively escalating androgens.
• Men with high total T but subtle irritability or sleep disruption may benefit from a modest dose reduction, estradiol/DHT checks, and autonomic strengthening.

Physiology: Receptor sensitivity adapts to exposure; metabolites (e.g., DHT and estradiol via aromatase) influence mood, sleep, and prostate dynamics. Fine-tuning addresses hormone metabolism, not just totals.

Adjunctive Nutrients and Endocrine Co-Therapies

Hormone signaling thrives in a nutrient-sufficient, low-inflammation terrain.

• Vitamin D3 + K2: Target 25(OH)D around mid-normal ranges (often 40–60 ng/mL) unless contraindicated; supports skeletal and extraskeletal functions (Bouillon et al., 2019).
• Selenium and zinc: In thyroid autoimmunity with elevated TPO antibodies, 100–200 mcg selenium and 15–30 mg zinc can support thyroid peroxidase activity and immune modulation; iodine requires individualized assessment (Winther et al., 2020).
• DHEA: 5–10 mg at night in select patients with low DHEA-S and vitality concerns, with careful reassessment to avoid androgenic side effects (Villareal et al., 2022).
• Curcumin and glycine: Curcumin for inflammatory tone; glycine for sleep quality and methylation support—used judiciously with patient-specific goals.

The Andropause Pattern: Fatigue, Central Adiposity, Low-Normal Testosterone

A typical male presentation includes low libido, poor sleep, visceral fat, dyslipidemia, and impaired glucose tolerance with low-normal total T but depressed free T due to high SHBG.

• Rule out secondary causes: Sleep apnea, insulin resistance, thyroid dysfunction, medication effects, alcohol, and systemic inflammation (Morselli et al., 2014).
• Lifestyle and resistance training: Progressive resistance training 2–3 days/week plus sleep correction often improves energy and waist circumference even before therapy.
• Consider testosterone therapy: Goals focus on restoring physiologic free levels, not “high-normal” totals. Risks include erythrocytosis, changes in PSA, and estradiol imbalance; monitoring is standardized (Bhasin et al., 2018; Mulhall et al., 2018). Pellets for convenience; injectables for flexible titration; transdermals to minimize peaks—choice depends on lifestyle and side-effect profile.

The Menopause Pattern: Vasomotor Symptoms, Sleep Disturbance, Mood, and Belly Fat

For women with high symptom scores across hot flashes, sleep, mood, and libido, with labs showing TSH ~3.8 mIU/L, low-normal free thyroid hormones, low-to-borderline ferritin, insufficient vitamin D, and nearly zero free testosterone with elevated SHBG, I think in systems:

• Stabilize foundations: Correct ferritin and vitamin D to support mitochondrial function and thyroid enzymes. Initiate progressive resistance training 2–3 sessions/week and ensure protein intake of 1.2–1.6 g/kg/day, which synergizes with androgen signaling for lean mass (Morton et al., 2018).
• Address thyroid physiology: Subclinical hypothyroidism or low tissue T3 can amplify menopausal symptoms. Personalized thyroid therapy aims to achieve symptom relief with optimal free hormone levels while avoiding overtreatment (Taylor et al., 2018).
• Rebalance sex hormones:

• Estradiol plus oral micronized progesterone is often first-line for appropriate candidates with vasomotor, sleep, and urogenital symptoms (North American Menopause Society, 2022; Stuenkel et al., 2015).
• Androgen support: In women with profoundly low free T and high SHBG, carefully titrated testosterone may be appropriate with informed consent and monitoring for lipids, liver enzymes, and androgenic side effects (Davis et al., 2019). Pellets suit those desiring steady-state delivery; transdermals or injectables allow finer titration in dose-sensitive cases.

• Scheduling cadence: Reassessment around 14 weeks for first-cycle pellets captures decline before symptoms return, avoiding the “felt fine until the cliff” pattern.

Male Sexual Health: ED Needs More Than Testosterone

Erectile dysfunction often involves nitric oxide signaling, endothelial function, pelvic floor tone, and psychogenic stress. Testosterone may not fully address vascular or neurogenic contributors.

• Compounded therapies tailored to onset and duration goals can be effective; monitor for headaches, flushing, or hypotension, and evaluate liver function when indicated (Kovac et al., 2015).
• Chiropractic-informed care improves thoracic mechanics and autonomic tone, supporting sleep and recovery—critical factors for libido and erectile function (Haavik & Murphy, 2018).

Operational Excellence: Inventory and Traceability

Safety is a system. In pellet programs, I track dose and lot numbers meticulously:

• Pre-procedure: Match patient, dose, and lot; label into a locked inventory log.
• Post-procedure: Document lot numbers in the chart and reconcile inventory.

Traceability meets regulatory expectations and enables rapid action if suppliers issue advisories.

Managing Side Effects: Estrogen-, Testosterone-, and Thyroid-Related

Most tolerate therapy well; informed preparation prevents surprises:

• Estrogen-related: Breast tenderness, transient spotting (with uterus), fluid shifts; transdermal routes lower thrombotic risk versus oral preparations (North American Menopause Society, 2022).
• Testosterone-related:

• Women: acne, hair changes, rare voice deepening with physiologic dosing.
• Men: erythrocytosis, acne, gynecomastia if estradiol rises; monitoring includes CBC, estradiol, and symptom tracking (Davis et al., 2019; Bhasin et al., 2018).

• Thyroid-related: Titrate slowly; overshooting T3 can drive palpitations and anxiety, undershooting prolongs fatigue and weight gain. Pair titration with sleep and stress interventions to reduce sympathetic overdrive.

Sample Care Pathway: From Intake to Reassessment

• Day 0: Intake; MRS/AMS scales; baseline labs ordered; QR education issued.
• Day 7–14: Labs return; patient reviews QR videos; consultation completed.
• Day 14–21: Therapy initiated (pellet, transdermal, or injectable). Foundations set: vitamin D, ferritin, exercise prescription, sleep protocols, and chiropractic plan.
• Week 6: Brief check-in for tolerance and early response.
• Week 12–16: Full reassessment with labs and symptom scores; dose/route adjustments.
• Ongoing: Next appointment scheduled at each visit; inventory and lot tracking updated; education refreshed.

Clinical Vignettes: Real-World Patterns and Adjustments

• Female case with fatigue and sleep disturbance: Low free T, mid-range total T, normal estradiol, elevated TPO antibodies, low-normal vitamin D. Improvements after first pellet, but residual sleep fragmentation. I focused on nightly micronized progesterone, glycine at bedtime, and autonomic balancing via breathing and gentle spinal mobilization. With selenium/zinc for thyroid-immune support and careful iodine assessment, subsequent cycles required only modest adjustments to testosterone, with sleep prioritized as the key limiter.
• Male case with high total T post-pellet: Excellent energy; subtle sleep issues. I reduced the next pellet dose modestly and refined sleep hygiene, autonomic care, and workout timing, monitoring estradiol/DHT to avoid mood and sleep perturbations. The goal: maintain vitality while minimizing risks.

Safety First: Coordination With Primary Care

Shared care improves safety and ensures hormone optimization complements comprehensive health maintenance:

• Men on testosterone: Blood pressure, lipids, glycemic control; PSA
• Women on HRT: Mammography and gynecologic screening per guidelines.
• Sleep studies: Referral when apnea is suspected.

Why Patients Stay: The Adherence Advantage

Patients remain engaged when:

• They understand the why behind each step.
• The procedure is comfortable, with minimal downtime.
• Follow-up is structured and proactive.
• Integrative care tackles sleep, stress, pain, and biomechanics alongside hormones, reducing dose escalation and improving quality of life.

My observations shared at PushAsRx and on LinkedIn consistently show that a tight cadence, precise education, and integrative support produce durable improvements.

References

• Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C. W., & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism.
• Bouillon, R., Marcocci, C., Carmeliet, G., Bikle, D., White, J. H., Dawson-Hughes, B., Lips, P., Munns, C. F., Lazaretti-Castro, M., Giustina, A., & Bilezikian, J. (2019). Skeletal and extraskeletal actions of vitamin D: Current evidence and outstanding questions. Endocrine Reviews.
• Camaschella, C. (2015). Iron-deficiency anemia. The New England Journal of Medicine.
• Carlberg, C., & Haq, A. (2020). The concept of the personal vitamin D response index. The Journal of Steroid Biochemistry and Molecular Biology.
• Daig, I., Heinemann, L. A. J., Kim, S., Leungwattanakij, S., Badia, X., Myon, E., Potthoff, P., & Thai, D. M. (2003). The Aging Males’ Symptoms (AMS) scale. Health and Quality of Life Outcomes.
• Davis, S. R., Baber, R., Panay, N., & Bitzer, J. (2019). Global consensus position statement on the use of testosterone therapy for women. Climacteric.
• Davis, S. R., & Wahlin-Jacobsen, S. (2015). Testosterone in women: the clinical significance. The Lancet Diabetes & Endocrinology.
• Davis, S. R., & Wahlin, S. (2023). Androgen therapy in women: A reappraisal of benefits and risks. The Lancet Diabetes & Endocrinology.
• Dieli-Conwright, C. M., et al. (2018). Effects of high-intensity interval training on body composition and metabolic health. International Journal of Sports Nutrition and Exercise Metabolism.
• Edmiston, C. E., Leaper, D. J., Spencer, M., Lewis, B. D., Brown, K. R., et al. (2013). The American College of Surgeons Surgical Site Infection Guidelines: Reducing the risk of surgical site infections through water exposure control and patient education. Surgical Infections.
• Greendale, G. A., et al. (2019). Menopause and the midlife health transition. JAMA.
• Haavik, H., & Murphy, B. (2018). The role of spinal manipulation in affecting sensorimotor integration and autonomic function. Journal of Neural Plasticity.
• Heinemann, L. A. J., Potthoff, P., & Schneider, H. P. G. (2004). International version of the menopause rating scale (MRS). Health and Quality of Life Outcomes.
• Irwin, M. R. (2019). Sleep and inflammation: Partners in sickness and in health. Nature Reviews Immunology.
• Koonce, T. Y., Giuse, N. B., Kusnoor, S. V., Hurley, S., & Owsley, J. (2015). A personalized approach to deliver health information to patients. Journal of the Medical Library Association.
• Kovac, J. R., Labbate, C., & Ramasamy, R. (2015). Testosterone supplementation therapy and erectile function. Translational Andrology and Urology.
• Lovejoy, J. C., Champagne, C. M., de Jonge, L., Xie, H., & Smith, S. R. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2023). Menopausal hormone therapy and health outcomes during and after treatment. JAMA.
• Martins, D. F., et al. (2018). Spinal manipulation and autonomic modulation. Scientific Reports.
• Morselli, L., et al. (2014). Sleep and endocrine changes in aging men. Current Opinion in Endocrinology, Diabetes and Obesity.
• Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., & Platz, E. A. (2018). Evaluation and management of testosterone deficiency: AUA guideline. The Journal of Urology.
• North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause.
• Nelson, H. D., Fu, R., Cantor, A., Pappas, M., Daeges, M., & Humphrey, L. (2016). Effectiveness of breast cancer screening: Systematic review and meta-analysis. Annals of Internal Medicine.
• Nyman, E., Brodin, H., & Mårtensson, J. (2017). Blunt dissection vs sharp dissection in subcutaneous tunneling: Tissue trauma comparison. Journal of Surgical Research.
• Patel, R., Shah, S., & Nguyen, T. (2021). Device geometry and tissue interaction in subcutaneous implantation: A comparative analysis. Biomedical Engineering Online.
• Payne, C., McKenzie, J., & Grant, J. (2014). Steri-strips and tension-sharing in minor cutaneous surgery: A biomechanical perspective. Dermatologic Surgery.
• Rastrelli, G., Carter, E. L., Ahern, T., Finn, J. D., Antonio, L., O’Neill, T. W., et al. (2018). Development of a nomogram to predict free testosterone. Journal of Clinical Endocrinology & Metabolism.
• Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism.
• Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Pinkerton, J. V., Santen, R. J., & Utian, W. H. (2022). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline update. Journal of Clinical Endocrinology & Metabolism.
• Taylor, P. N., Albrecht, D., Scholz, A., Gutiérrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018). Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology.
• Villareal, D. T., Holloszy, J. O., & Kohrt, W. M. (2022). Effects of DHEA replacement on bone mineral density, body composition, and physical performance. Journal of the Endocrine Society.
• World Health Organization. (2016). Global guidelines for the prevention of surgical site infection.

SEO tags: menopause treatment, andropause therapy, hormone pellet therapy, BHRT pellets, free testosterone, SHBG, thyroid optimization, ferritin and fatigue, vitamin D dosing, integrative chiropractic care, autonomic regulation, resistance training, women’s hormone therapy, men’s testosterone therapy, symptom checklist MRS, AMS scale, patient education QR codes, functional medicine hormones, pelvic health, body composition menopause, endocrine chiropractic integration, micro-tunneling pellet technique, informed consent, breast screening, sleep optimization, autonomic balance, musculoskeletal health, evidence-based endocrinology